Publications and Presentations

Journal Articles

Grimison P , al et. Testosterone deficiency and quality of life in Australian testicular cancer survivors. Internal Medicine Journal. Forthcoming.

Grimison PS, Stockler MR, Chatfield M, Thomson DB, Gebski V, Friedlander M, Boland AL, Houghton B, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology 2014; 25(1): 143–148.

Chambers SK, Smith DP, Berry M, Lepore SJ, Foley E, Clutton S, McDowall R, Occhipinti S, Frydenberg M, Gardiner RA. A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer. BMC Cancer 2013; 13: 89.

Grimison P, Houghton B, Chatfield M, Toner GC, Davis ID, Martin J, Hovey E, Stockler MR. Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU International 2013; 112(2): E35–E43.

Holzner B, Efficace F, Basso U, Johnson CD, Aaronson NK, Arraras JI, Smith AB, Chow E, Oberguggenberger AS, Bottomley A, Steiner H, Incrocci L, Giesinge JM. Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26. Quality of Life Research 2013; 22(2): 369–378.

Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CSB, Patel MI, Davis ID, MR Stockler. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU International 2013; 111(6): 977–983.

Olver IN, Grimison P, Chatfield M, Stockler MR, Toner GC, Gebski V, Harrup R, Underhill C, Kichenadasse G, Singhal N, Davis ID, Boland A, McDonald A, Thomson D, for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer 2013; 21(6): 1561–1568.

Smith AB, King M, Butow P, Grimison P, Olver I. Reduced quality of life in internet-panel controls [research letter]. Epidemiology 2013; 24(3): 462–463.

Smith A, King M, Butow P, Luckett T, Grimison P, Toner GC, Stockler M, Hovey E, Stubbs J, Hruby G, Gurney H, Turner S, Alam M, Cox K, Olver I. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. PsychoOncology 2013; 22(11): 2557-2564.

Conference abstracts and presentations

Davis ID, Long A, Martin A, Espinoza D, Yip S, Kichenadasse G, Thompson JF, Harrison ML, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro JD, Stockler MR, Australian & New Zealand Urogenital and Prostate Cancer Trials Group. EVERSUN: a phase 2 trial of everolimus alternating with sunitinib as first line therapy for advanced renal cell carcinoma (ANZUP trial 0901). Genitourinary Cancers Symposium; 30 Jan–1 Feb 2014; San Francisco.

Horvath L, Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Qu W, Boyer MJ, Stockler MR, Pavlakis N, Marx GM, Gowda GMH, Gurney H, Clark SJ, Swarbrick A, Daly RJ. Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer. Genitourinary Cancers Symposium; 30 Jan–1 Feb 2014; San Francisco.

Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes R, Chatfield MD, Boyer MJ, Stockler MR, Marx GM, Gurney H, GMH Gowda, Molloy P, Horvath L, Clark SJ, PRIMe Consortium. Methylated glutathione s-transferase 1 as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrateresistant prostate cancer. Genitourinary Cancers Symposium; 30 Jan–1 Feb 2014; San Francisco.

Yip S, Pavlakis N, Harvie R, Martin A, Jovanovic L, Hudson A, Thompson JF, Nelson C, Long A, Steer C, Harrison ML, Kannourakis G, Goldstein D, Kichenadasse G, Lowenthal RM, Stockler MR, Davis ID. Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma: ANZUP 0901—the EVERSUN trial. Genitourinary Cancers Symposium; 30 Jan–1 Feb 2014; San Francisco.

Sengupta S, Blinman P, Thompson J, France T, Martin A, Davis I, Stockler M. Patients’ and their doctors’ preferences for adjuvant sorafenib after resection of intermediate to high risk RCC: what makes it worthwhile? Urological Society of Australia and New Zealand 66th Annual Scientific Meeting; 13–16 Apr 2013; Melbourne.

Smith A, King M, Butow P, Luckett T, Grimison P, Toner G, Stockler M, Hovey E, Stubbs J, Hruby G, Gurney H, Turner S, Alam M, Cox K, Olver I. The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. IPOS 15th World Congress of Psycho-Oncology; 4-8 Nov 2013; Rotterdam.